Documentation

Library

337

Papers

cited by this build

185

Supply a number

the rest support quoted prose

Every paper this archive cites, in one list. Ranked by what each contributed rather than by date, because a reader auditing this build should meet the paper it leans on hardest first. A citation that no longer resolves is listed as unresolved rather than quietly dropped.

The whole bibliography

The list below is server-rendered in full, so it is readable with scripts off and by find-in-page. The filter only hides rows; it never fetches.

337 papers

01
Molecular biology of 5-HT receptors
Boess FG, Martin IL · Neuropharmacology 1994 · PMID 7984267
115 measurements at 13 targets · Measurements
5-Methoxytryptamine, Bromocriptine, DOB, DOI, DOM, Ergonovine, Ergotamine, Lisuride, LSD, Methysergide, Tryptamine
02
Landmark
Psychedelics and the human receptorome
Ray TS · PloS one 2010 · PMID 20126400
98 measurements at 30 targets · Measurements
Dimethyltryptamine (DMT), DiPT, Ibogaine, Lisuride, LSD, Mescaline, N,N-Dipropyltryptamine (DPT), Psilocin, Salvinorin A
Why it matters · written by this site
A reference work rather than a result: it reports the affinity of twenty-five psychedelics at fifty-one receptors, transporters and ion channels assayed by the NIMH Psychoactive Drug Screening Program, and adds literature data on ten more p. Its argument is that the selectivity usually assumed for these compounds is not there — the drugs surveyed interact with forty-two of the forty-nine sites broadly assayed, and the paper proposes that this diversity of receptor interaction is what underlies the qualitative diversity of the drugs themselves p. It also introduces a normalisation that factors potency out of a Ki so that two compounds' multi-receptor profiles can be compared as shapes rather than as magnitudes p. It is the second-largest single contributor of measurements to this archive a.
Verified Abstract read in full via PubMed (PMID 20126400, DOI 10.1371/journal.pone.0009019); the paper is open access in PMC2814854 but the full text was not read. Every claim above is stated in the abstract, including the counts twenty-five, fifty-one, ten, forty-two and forty-nine. The normalisation method is described in the abstract as introduced there; how it works was not examined. Nothing is claimed about the method's reception or use elsewhere.
Not supported Whether the normalisation has been adopted by others, and whether the selectivity claim is now the consensus. Neither is in the abstract.
03
Landmark
Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs
Klein LM, Cozzi NV, Daley PF et al. · Neuropharmacology 2018 · PMID 29499272
40 measurements at 24 targets · Measurements
5-MeO-DALT, DALT
Why it matters · written by this site
A study that puts binding and behavior side by side rather than inferring one from the other. Ten ring-substituted N,N-diallyltryptamines were assayed at forty-five receptor and transporter sites and separately tested in mice for the head twitch response, a 5-HT2A-mediated behavior used as a proxy for hallucinogen effect p. The finding that matters is a negative one: head twitch potency did not correlate with either 5-HT2A or 5-HT1A binding affinity on its own, and only a regression treating the two together accounted for it, with 5-HT2A contributing positively and 5-HT1A negatively p. The authors read this as 5-HT1A activation buffering the effect of tryptamine hallucinogens p. It is the largest single contributor of measurements to the archive's DALT records a.
Verified Abstract read in full via PubMed (PMID 29499272, DOI 10.1016/j.neuropharm.2018.02.028). The forty-five sites, the HTR rank order, the absence of a single-receptor correlation, and the signs of the two regression contributions are stated there. The abstract's receptor subscripts are lost in PubMed's plain text -- it renders '5-HT' where the paper prints a subscripted subtype -- so the two subtypes named above are taken from the sentences where the abstract spells them out, and no subtype is asserted from a passage where the digit is missing.
Not supported The R value of the regression, which appears in the abstract as 'R = 0.8729' with the exponent lost, so it cannot be told whether the paper reported R or R². Neither is quoted.
04
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes
Millan MJ, Maiofiss L, Cussac D et al. · The Journal of pharmacology and experimental therapeutics 2002 · PMID 12388666
40 measurements at 20 targets · Measurements
Bromocriptine, Lisuride
05
Deconstruction of lysergic acid diethylamide
Basargin AG, Domokosa A, Hennessey JJ et al. · Proceedings of the National Academy of Sciences of the United States of America 2026 · PMID 42709856
28 measurements at 9 targets · Measurements
UCD0076, UCD0094 (RU 28306), UCD0120, UCD0179, UCD0829, UCD0830
06
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors
Egan C, Grinde E, Dupre A et al. · Synapse (New York, N.Y.) 2000 · PMID 10611640
26 measurements at 2 targets · Measurements
5-Methoxytryptamine, DOB, DOI, DOM, Lisuride, LSD, Methysergide, Tryptamine
07
Landmark
Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)
Rickli A, Luethi D, Reinisch J et al. · Neuropharmacology 2015 · PMID 26318099
26 measurements at 10 targets · Measurements
2C-H, 2C-I, LSD, Mescaline
Why it matters · written by this site
The paper that characterised the NBOMe compounds when they were new and their pharmacology was, in its own words, poorly defined p. It measures each 2C phenethylamine beside its N-2-methoxybenzyl analogue and beside LSD at monoamine receptors and transporters, so the effect of the substitution can be read directly: adding the N-2-methoxybenzyl group raises affinity at 5-HT2A, 5-HT2C, α1, D1–D3 and H1 and at the monoamine transporters, while lowering it at 5-HT1A and TAAR1 p. The result is a set of very potent 5-HT2A agonists, EC50 0.04–0.5 μM, resembling LSD in their 5-HT2A and α1 affinity but not in their dopamine receptor binding p. This archive holds both halves of that comparison, which is why the paper appears on several 2C and NBOMe dossiers at once a.
Verified Abstract read in full via PubMed (PMID 26318099, DOI 10.1016/j.neuropharm.2015.08.034). The receptor lists, the direction of each affinity change, and the EC50 range 0.04–0.5 μM are all stated there. The abstract notes that TAAR1 was assayed with rat/mouse receptors rather than human, which is why no claim is made here about human TAAR1.
Not supported The individual Ki values, which are in the paper's tables and not in the abstract. Where this archive shows an NBOMe affinity it comes from the ingested rows, not from this note.
08
RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist
Bonhaus DW, Weinhardt KK, Taylor M et al. · Neuropharmacology 1997 · PMID 9225287
25 measurements at 3 targets · Measurements
5-Methoxytryptamine, Ergotamine, Lisuride, Methysergide, Tryptamine
09
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors
Knight AR, Misra A, Quirk K et al. · Naunyn-Schmiedeberg's archives of pharmacology 2004 · PMID 15322733
21 measurements at 3 targets · Measurements
DOB, DOI, Ergotamine, LSD, Methysergide, Tryptamine
10
Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
Puigseslloses P, Nadal-Gratacós N, Fumàs B et al. · Molecular psychiatry 2026 · PMID 41120735
20 measurements at 5 targets · Measurements
5-Bromo-DMT (5-Br-DMT), 5-Chloro-DMT (5-Cl-DMT), 5-Fluoro-DMT (5-F-DMT), Dimethyltryptamine (DMT)
11
Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition
Breivogel CS, Childers SR · The Journal of pharmacology and experimental therapeutics 2000 · PMID 10991998
20 measurements at 1 target · Measurements
CP 55940, Tetrahydrocannabinol (THC), WIN 55212-2
12
Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin
McKenna DJ, Peroutka SJ · The Journal of neuroscience : the official journal of the Society for Neuroscience 1989 · PMID 2795135
19 measurements at 2 targets · Measurements
Dimethyltryptamine (DMT), DOET, DOI, DOM, LSD, Mescaline, Psilocin, Psilocybin, Tryptamine
13
Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro
Janowsky A, Eshleman AJ, Johnson RA et al. · Psychopharmacology 2014 · PMID 24488404
19 measurements at 8 targets · Measurements
Dimethyltryptamine (DMT), DOM, LSD
14
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)
Nichols DE, Frescas S, Marona-Lewicka D et al. · Journal of medicinal chemistry 2002 · PMID 12213075
17 measurements at 17 targets · Measurements
LSD
15
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors
Nelson DL, Lucaites VL, Wainscott DB et al. · Naunyn-Schmiedeberg's archives of pharmacology 1999 · PMID 9933142
16 measurements at 3 targets · Measurements
DOB, DOC (2,5-dimethoxy-4-chloroamphetamine), DOI, DOPR
16
Landmark
Structural basis of opioid receptor activation by PCP and ketamine
Jiang Q, Han J, Fine EJ et al. · Nature structural & molecular biology 2026 · PMID 42332075
16 measurements at 4 targets · Measurements
3-HO-PCP, Ketamine, Phencyclidine (PCP)
Why it matters · written by this site
The reason ketamine's opioid receptor rows in this archive stopped being blank. Before it, every ChEMBL record for ketamine at KOR, MOR and DOR was a screening result quarantined as a non-result — 'Inhibition < 50% @ 10 uM and thus dose-response curve not measured' — so the archive held the question and none of the answer a. This paper measures it: cryo-EM structures of human KOR and MOR bound to (S)-ketamine and to PCP, with binding affinities and cAMP potencies for PCP and all three ketamine forms at all three opioid receptors p. It also reports the ligand-free state of KOR, which serves as a negative control for the ligand densities in the bound structures p. Sixteen of its measurements are held here, transcribed from the paper rather than from a database a.
Verified Full text read from the publisher PDF: Results, Discussion, and the Methods sections covering membrane preparation, saturation and competition binding, the cAMP inhibition assay and the warm water tail withdrawal assay. The quarantine comment quoted above is this archive's own stored `activity_comment` on those ChEMBL rows, not the paper's words. The structures, the apo KOR control and its stated purpose are in the Results. See tools/literature_measurements.json for what was and was not taken from it.
Not supported The paper's stereoselectivity result — that (S)-ketamine binds and activates opioid receptors more strongly than (R)-ketamine — cannot be shown on this site, because the archive holds racemic ketamine and neither enantiomer. That absence is recorded in tools/literature_measurements.json rather than papered over.
17
The 5-HT7 receptor: orphan found
Eglen RM, Jasper JR, Chang DJ et al. · Trends in pharmacological sciences 1997 · PMID 9149537
15 measurements at 1 target · Measurements
5-Methoxytryptamine, Lisuride, LSD, Methysergide
18
Marine Inspired 2-(5-Halo-1H-indol-3-yl)-N,N-dimethylethanamines as Modulators of Serotonin Receptors: An Example Illustrating the Power of Bromine as Part of the Uniquely Marine Chemical Space
Ibrahim MA, El-Alfy AT, Ezel K et al. · Marine drugs 2017 · PMID 28792478
14 measurements at 7 targets · Measurements
Ergotamine, Methysergide
19
Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human gamma-aminobutyric acid type A receptors
Ebert B, Thompson SA, Saounatsou K et al. · Molecular pharmacology 1997 · PMID 9396785
14 measurements at 1 target · Measurements
Muscimol
20
Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes
Burt DR, Creese I, Snyder SH · Molecular pharmacology 1976 · PMID 995128
13 measurements at 2 targets · Measurements
Bromocriptine, Ergocristine, Ergonovine, Ergotamine, LSD, Lysergic acid amide (LSA), Methysergide
21
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
Setola V, Hufeisen SJ, Grande-Allen KJ et al. · Molecular pharmacology 2003 · PMID 12761331
13 measurements at 11 targets · Measurements
MDMA, Methysergide
22
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells
Boess FG, Monsma FJ Jr, Carolo C et al. · Neuropharmacology 1997 · PMID 9225298
12 measurements at 1 target · Measurements
5-Methoxytryptamine, Ergotamine, Lisuride, LSD, Methysergide, Tryptamine
23
Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain
To ZP, Bonhaus DW, Eglen RM et al. · British journal of pharmacology 1995 · PMID 7647964
12 measurements at 1 target · Measurements
5-Methoxytryptamine, Ergotamine, Lisuride, LSD, Methysergide, Tryptamine
24
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells
Porter RH, Benwell KR, Lamb H et al. · British journal of pharmacology 1999 · PMID 10498829
12 measurements at 3 targets · Measurements
DOB, DOI, LSD, Tryptamine
25
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype
Shen Y, Monsma FJ Jr, Metcalf MA et al. · The Journal of biological chemistry 1993 · PMID 8394362
10 measurements at 1 target · Measurements
5-Methoxytryptamine, Bromocriptine, Lisuride, Methysergide, Tryptamine
26
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences
Wainscott DB, Lucaites VL, Kursar JD et al. · The Journal of pharmacology and experimental therapeutics 1996 · PMID 8632342
10 measurements at 3 targets · Measurements
5-Methoxytryptamine, DOI, Methysergide, Tryptamine
27
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta
Weinshank RL, Zgombick JM, Macchi MJ et al. · Proceedings of the National Academy of Sciences of the United States of America 1992 · PMID 1565658
9 measurements at 2 targets · Measurements
5-Methoxytryptamine, Methysergide, Tryptamine
28
Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines
Kolaczynska KE, Luethi D, Trachsel D et al. · Frontiers in pharmacology 2019 · PMID 31849671
9 measurements at 8 targets · Measurements
TMA-2
29
Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor
Herrick-Davis K, Grinde E, Gauthier C et al. · Annals of the New York Academy of Sciences 1998 · PMID 9928251
8 measurements at 1 target · Measurements
5-Methoxytryptamine, DOB, Methysergide, Tryptamine
30
A functional test identifies dopamine agonists selective for D3 versus D2 receptors
Sautel F, Griffon N, Lévesque D et al. · Neuroreport 1995 · PMID 7756621
8 measurements at 2 targets · Measurements
Bromocriptine, Lisuride
31
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase
Bard JA, Zgombick J, Adham N et al. · The Journal of biological chemistry 1993 · PMID 8226867
7 measurements at 3 targets · Measurements
5-Methoxytryptamine, Methysergide, Tryptamine
32
The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors
Bonhaus DW, Bach C, DeSouza A et al. · British journal of pharmacology 1995 · PMID 7582481
7 measurements at 3 targets · Measurements
Methysergide
33
Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor
Zgombick JM, Schechter LE, Macchi M et al. · Molecular pharmacology 1992 · PMID 1513320
6 measurements at 1 target · Measurements
5-Methoxytryptamine, DOI, Ergonovine, Ergotamine, Methysergide, Tryptamine
34
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs
Monsma FJ Jr, Shen Y, Ward RP et al. · Molecular pharmacology 1993 · PMID 7680751
6 measurements at 1 target · Measurements
5-Methoxytryptamine, Lisuride, Methysergide, Tryptamine
35
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists
Manera C, Cascio MG, Benetti V et al. · Bioorganic & medicinal chemistry letters 2007 · PMID 17942307
6 measurements at 2 targets · Measurements
HU-210, Rimonabant, WIN 55212-2
36
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling
Stern E, Muccioli GG, Millet R et al. · Journal of medicinal chemistry 2006 · PMID 16392793
6 measurements at 1 target · Measurements
CP 55940, HU-210, WIN 55212-2
37
Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties
Mauler F, Mittendorf J, Horváth E et al. · The Journal of pharmacology and experimental therapeutics 2002 · PMID 12065738
6 measurements at 2 targets · Measurements
CP 55940, HU-210, WIN 55212-2
38
Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain
Erlander MG, Lovenberg TW, Baron BM et al. · Proceedings of the National Academy of Sciences of the United States of America 1993 · PMID 7682702
6 measurements at 2 targets · Measurements
DOI, Ergotamine, Methysergide
39
Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein
Leonhardt S, Herrick-Davis K, Titeler M · Journal of neurochemistry 1989 · PMID 2664084
6 measurements at 2 targets · Measurements
DOB, Ergotamine, Methysergide
40
3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism
Wiley JL, Selley DE, Wang P et al. · The Journal of pharmacology and experimental therapeutics 2012 · PMID 22085649
6 measurements at 2 targets · Measurements
CP 55940, Rimonabant
41
Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling
Hirst WD, Abrahamsen B, Blaney FE et al. · Molecular pharmacology 2003 · PMID 14645659
6 measurements at 1 target · Measurements
5-Methoxytryptamine, LSD
42
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
Rothman RB, Baumann MH, Savage JE et al. · Circulation 2000 · PMID 11104741
6 measurements at 3 targets · Measurements
Ergotamine, Methysergide
43
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor
Iwamura H, Suzuki H, Ueda Y et al. · The Journal of pharmacology and experimental therapeutics 2001 · PMID 11160626
6 measurements at 2 targets · Measurements
WIN 55212-2
44
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications
Toll L, Berzetei-Gurske IP, Polgar WE et al. · NIDA research monograph 1998 · PMID 9686407
6 measurements at 6 targets · Measurements
Bromocriptine
45
Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells
Bolden C, Cusack B, Richelson E · The Journal of pharmacology and experimental therapeutics 1992 · PMID 1346637
6 measurements at 5 targets · Measurements
Scopolamine
46
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
Breivogel CS, Griffin G, Di Marzo V et al. · Molecular pharmacology 2001 · PMID 11408610
5 measurements at 1 target · Measurements
Cannabinol, CP 55940, HU-210, JWH-073, WIN 55212-2
47
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase
Adham N, Kao HT, Schecter LE et al. · Proceedings of the National Academy of Sciences of the United States of America 1993 · PMID 8380639
5 measurements at 1 target · Measurements
5-Methoxytryptamine, DOI, Ergotamine, Methysergide, Tryptamine
48
The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
Roth BL, Gibbons S, Arunotayanun W et al. · PloS one 2013 · PMID 23527166
5 measurements at 3 targets · Measurements
Ketamine, MXE, Phencyclidine (PCP)
49
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor
Griffin G, Tao Q, Abood ME · The Journal of pharmacology and experimental therapeutics 2000 · PMID 10688601
5 measurements at 1 target · Measurements
CP 55940, WIN 55212-2
50
Pharmacological characterization of designer cathinones in vitro
Simmler LD, Buser TA, Donzelli M et al. · British journal of pharmacology 2013 · PMID 22897747
5 measurements at 4 targets · Measurements
MDMA
51
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists
Kim MG, Bodor ET, Wang C et al. · Journal of medicinal chemistry 2003 · PMID 12747793
5 measurements at 5 targets · Measurements
Arecoline
52
Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors
Glusa E, Pertz HH · British journal of pharmacology 2000 · PMID 10821800
5 measurements at 4 targets · Measurements
Methysergide
53
Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells
Lazareno S, Buckley NJ, Roberts FF · Molecular pharmacology 1990 · PMID 2250662
5 measurements at 4 targets · Measurements
Scopolamine
54
Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine
Largent BL, Gundlach AL, Snyder SH · The Journal of pharmacology and experimental therapeutics 1986 · PMID 3016248
5 measurements at 1 target · Measurements
Phencyclidine (PCP)
55
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor
Kohen R, Metcalf MA, Khan N et al. · Journal of neurochemistry 1996 · PMID 8522988
4 measurements at 1 target · Measurements
5-Methoxytryptamine, Bromocriptine, Dimethyltryptamine (DMT), Methysergide
56
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase
Plassat JL, Amlaiky N, Hen R · Molecular pharmacology 1993 · PMID 8394987
4 measurements at 1 target · Measurements
5-Methoxytryptamine, Bromocriptine, Ergotamine, Methysergide
57
Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues
Wallach J, Kang H, Colestock T et al. · PloS one 2016 · PMID 27314670
4 measurements at 1 target · Measurements
Ketamine, Phencyclidine (PCP)
58
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation
Runyon SP, Mosier PD, Roth BL et al. · Journal of medicinal chemistry 2008 · PMID 18847250
4 measurements at 1 target · Measurements
DOB, DOI
59
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman PK · British journal of anaesthesia 2005 · PMID 16051647
4 measurements at 2 targets · Measurements
Bromocriptine, Methysergide
60
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols
Cussac D, Newman-Tancredi A, Quentric Y et al. · Naunyn-Schmiedeberg's archives of pharmacology 2002 · PMID 11882920
4 measurements at 2 targets · Measurements
DOI, Lisuride
61
[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum
Hemedah M, Coupar IM, Mitchelson FJ · British journal of pharmacology 1999 · PMID 10051134
4 measurements at 1 target · Measurements
5-Methoxytryptamine, LSD
62
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)
Hillard CJ, Manna S, Greenberg MJ et al. · The Journal of pharmacology and experimental therapeutics 1999 · PMID 10336536
4 measurements at 2 targets · Measurements
CP 55940, WIN 55212-2
63
Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release
Stefano GB, Salzet B, Salzet M · Brain research 1997 · PMID 9125406
4 measurements at 1 target · Measurements
CP 55940, WIN 55212-2
64
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity
Bresink I, Danysz W, Parsons CG et al. · Neuropharmacology 1995 · PMID 7566488
4 measurements at 1 target · Measurements
Ketamine, Phencyclidine (PCP)
65
5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture
Sebben M, Ansanay H, Bockaert J et al. · Neuroreport 1994 · PMID 7696602
4 measurements at 2 targets · Measurements
5-Methoxytryptamine, LSD
66
A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms
Lovenberg TW, Baron BM, de Lecea L et al. · Neuron 1993 · PMID 8398139
4 measurements at 2 targets · Measurements
Ergotamine, Methysergide
67
Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization
Matthes H, Boschert U, Amlaiky N et al. · Molecular pharmacology 1993 · PMID 8450829
4 measurements at 2 targets · Measurements
Ergotamine, Methysergide
68
Distinct 5-HT(1B) and 5-HT(1D) serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors
Hamblin MW, McGuffin RW, Metcalf MA et al. · Molecular and cellular neurosciences 1992 · PMID 19912901
4 measurements at 2 targets · Measurements
5-Methoxytryptamine, Ergotamine
69
Antipsychotic occupancy of dopamine receptors in schizophrenia
Nord M, Farde L · CNS neuroscience & therapeutics 2011 · PMID 21143431
4 measurements at 1 target · Measurements
Bromocriptine
70
Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model
Wang H, Duffy RA, Boykow GC et al. · Journal of medicinal chemistry 2008 · PMID 18363352
4 measurements at 2 targets · Measurements
Rimonabant
71
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist
Roth BL, Baner K, Westkaemper R et al. · Proceedings of the National Academy of Sciences of the United States of America 2002 · PMID 12192085
4 measurements at 3 targets · Measurements
Salvinorin A
72
Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus
Blondel O, Gastineau M, Dahmoune Y et al. · Journal of neurochemistry 1998 · PMID 9603189
4 measurements at 4 targets · Measurements
5-Methoxytryptamine
73
Cloning and expression of a human serotonin 5-HT4 receptor cDNA
Van den Wyngaert I, Gommeren W, Verhasselt P et al. · Journal of neurochemistry 1997 · PMID 9349523
4 measurements at 1 target · Measurements
5-Methoxytryptamine
74
Pharmacological comparison between [3H]GR 113808 binding sites and functional 5-HT4 receptors in neurons
Ansanay H, Sebben M, Bockaert J et al. · European journal of pharmacology 1996 · PMID 8867105
4 measurements at 1 target · Measurements
5-Methoxytryptamine
75
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception
Codd EE, Shank RP, Schupsky JJ et al. · The Journal of pharmacology and experimental therapeutics 1995 · PMID 7562497
4 measurements at 4 targets · Measurements
Dextromethorphan
76
hERG Blockade by Iboga Alkaloids
Alper K, Bai R, Liu N et al. · Cardiovascular toxicology 2016 · PMID 25636206
3 measurements at 1 target · Measurements
Ibogaine, Noribogaine, Voacangine
77
Zebra finch CB1 cannabinoid receptor: pharmacology and in vivo and in vitro effects of activation
Soderstrom K, Johnson F · The Journal of pharmacology and experimental therapeutics 2001 · PMID 11259544
3 measurements at 1 target · Measurements
CP 55940, HU-210, WIN 55212-2
78
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation
Ruat M, Traiffort E, Leurs R et al. · Proceedings of the National Academy of Sciences of the United States of America 1993 · PMID 8397408
3 measurements at 1 target · Measurements
5-Methoxytryptamine, Lisuride, LSD
79
Pharmacological characterizations of the 'legal high' fluorolintane and isomers
Wallach J, Colestock T, Agramunt J et al. · European journal of pharmacology 2019 · PMID 31152702
3 measurements at 1 target · Measurements
Ketamine, Phencyclidine (PCP)
80
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents
Newman-Tancredi A, Audinot V, Chaput C et al. · The Journal of pharmacology and experimental therapeutics 1997 · PMID 9223553
3 measurements at 1 target · Measurements
Bromocriptine, Lisuride
81
Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT
Gozlan H, El Mestikawy S, Pichat L et al. · Nature 1983 · PMID 6225026
3 measurements at 1 target · Measurements
Methysergide, Tryptamine
82
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Luethi D, Trachsel D, Hoener MC et al. · Neuropharmacology 2018 · PMID 28720478
3 measurements at 3 targets · Measurements
LSD
83
Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review
Gillman PK · Headache 2010 · PMID 19925619
3 measurements at 3 targets · Measurements
Bromocriptine
84
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity
Dow RL, Carpino PA, Hadcock JR et al. · Journal of medicinal chemistry 2009 · PMID 19351113
3 measurements at 2 targets · Measurements
Rimonabant
85
Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations
Zhang Y, Burgess JP, Brackeen M et al. · Journal of medicinal chemistry 2008 · PMID 18512901
3 measurements at 2 targets · Measurements
Rimonabant
86
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors
Shoemaker JL, Joseph BK, Ruckle MB et al. · The Journal of pharmacology and experimental therapeutics 2005 · PMID 15901805
3 measurements at 2 targets · Measurements
CP 55940
87
3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects
De Vry J, Denzer D, Reissmueller E et al. · The Journal of pharmacology and experimental therapeutics 2004 · PMID 15140913
3 measurements at 2 targets · Measurements
CP 55940
88
A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole
May JA, Chen HH, Rusinko A et al. · Journal of medicinal chemistry 2003 · PMID 12954071
3 measurements at 2 targets · Measurements
DOI
89
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7)
Glennon RA · Journal of medicinal chemistry 2003 · PMID 12825922
3 measurements at 3 targets · Measurements
Methysergide
90
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
Rothman RB, Baumann MH, Dersch CM et al. · Synapse (New York, N.Y.) 2001 · PMID 11071707
3 measurements at 3 targets · Measurements
MDMA
91
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D et al. · Journal of medicinal chemistry 2000 · PMID 11101361
3 measurements at 3 targets · Measurements
Psilocin
92
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant
Bender E, Pindon A, van Oers I et al. · Journal of neurochemistry 2000 · PMID 10646498
3 measurements at 2 targets · Measurements
5-Methoxytryptamine
93
Muscarinic receptor binding sites of the M4 subtype in porcine lung parenchyma
Chelala JL, Kilani A, Miller MJ et al. · Pharmacology & toxicology 1998 · PMID 9834968
3 measurements at 1 target · Measurements
Scopolamine
94
[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors
Bonhaus DW, Berger J, Adham N et al. · Neuropharmacology 1997 · PMID 9225293
3 measurements at 1 target · Measurements
5-Methoxytryptamine
95
Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist
Doménech T, Beleta J, Palacios JM · Naunyn-Schmiedeberg's archives of pharmacology 1997 · PMID 9303569
3 measurements at 2 targets · Measurements
5-Methoxytryptamine
96
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Van Tol HH, Bunzow JR, Guan HC et al. · Nature 1991 · PMID 1840645
3 measurements at 2 targets · Measurements
Bromocriptine
97
Muscarinic receptor subtypes
Hulme EC, Birdsall NJ, Buckley NJ · Annual review of pharmacology and toxicology 1990 · PMID 2188581
3 measurements at 3 targets · Measurements
Atropine
98
Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues
Colestock T, Wallach J, Mansi M et al. · Drug testing and analysis 2018 · PMID 28513099
2 measurements at 1 target · Measurements
Ketamine, Phencyclidine (PCP)
99
Structural features for functional selectivity at serotonin receptors
Wacker D, Wang C, Katritch V et al. · Science (New York, N.Y.) 2013 · PMID 23519215
2 measurements at 1 target · Measurements
Ergotamine, LSD
100
Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity
Fan H, Kotsikorou E, Hoffman AF et al. · European journal of medicinal chemistry 2009 · PMID 18511157
2 measurements at 1 target · Measurements
HU-210, Rimonabant
101
Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor
Soderstrom K, Leid M, Moore FL et al. · Journal of neurochemistry 2000 · PMID 10854287
2 measurements at 1 target · Measurements
CP 55940, WIN 55212-2
102
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b)
Jasper JR, Kosaka A, To ZP et al. · British journal of pharmacology 1997 · PMID 9298538
2 measurements at 1 target · Measurements
5-Methoxytryptamine, Methysergide
103
Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization
Weiss HM, Haase W, Michel H et al. · FEBS letters 1995 · PMID 8549774
2 measurements at 1 target · Measurements
Ergotamine, Methysergide
104
The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants
Gerald C, Adham N, Kao HT et al. · The EMBO journal 1995 · PMID 7796807
2 measurements at 1 target · Measurements
5-Methoxytryptamine, LSD
105
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase
Tsou AP, Kosaka A, Bach C et al. · Journal of neurochemistry 1994 · PMID 7518496
2 measurements at 1 target · Measurements
5-Methoxytryptamine, Methysergide
106
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities
Compton DR, Rice KC, De Costa BR et al. · The Journal of pharmacology and experimental therapeutics 1993 · PMID 8474008
2 measurements at 1 target · Measurements
11-Hydroxy-delta9-tetrahydrocannabinol, Nabilone
107
Cloning and characterization of the rat 5-HT5B receptor. Evidence that the 5-HT5B receptor couples to a G protein in mammalian cell membranes
Wisden W, Parker EM, Mahle CD et al. · FEBS letters 1993 · PMID 8224165
2 measurements at 1 target · Measurements
LSD, Methysergide
108
Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes
Lovenberg TW, Erlander MG, Baron BM et al. · Proceedings of the National Academy of Sciences of the United States of America 1993 · PMID 8384716
2 measurements at 1 target · Measurements
Ergotamine, Methysergide
109
Characterization of 5-hydroxytryptamine1B receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of [3H]-5-hydroxytryptamine release
Matsumoto I, Combs MR, Jones DJ · The Journal of pharmacology and experimental therapeutics 1992 · PMID 1738111
2 measurements at 1 target · Measurements
5-Methoxytryptamine, Methysergide
110
The mouse 5HT5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family
Plassat JL, Boschert U, Amlaiky N et al. · The EMBO journal 1992 · PMID 1464308
2 measurements at 1 target · Measurements
Ergotamine, Methysergide
111
CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs
Lebar MD, Hahn KN, Mutka T et al. · Bioorganic & medicinal chemistry 2011 · PMID 21907583
2 measurements at 2 targets · Measurements
Ergotamine
112
Diaryl piperidines as CB1 receptor antagonists
Scott JD, Li SW, Wang H et al. · Bioorganic & medicinal chemistry letters 2010 · PMID 20018510
2 measurements at 2 targets · Measurements
Rimonabant
113
Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach
Meng T, Wang J, Peng H et al. · European journal of medicinal chemistry 2010 · PMID 20047779
2 measurements at 2 targets · Measurements
Rimonabant
114
Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern
Lange JH, van der Neut MA, Borst AJ et al. · Bioorganic & medicinal chemistry letters 2010 · PMID 20363132
2 measurements at 2 targets · Measurements
Rimonabant
115
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands
Foloppe N, Benwell K, Brooks TD et al. · Bioorganic & medicinal chemistry letters 2009 · PMID 19520572
2 measurements at 2 targets · Measurements
Rimonabant
116
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist
Griffith DA, Hadcock JR, Black SC et al. · Journal of medicinal chemistry 2009 · PMID 19102698
2 measurements at 1 target · Measurements
Rimonabant
117
Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors
Donohue SR, Varnäs K, Jia Z et al. · Bioorganic & medicinal chemistry letters 2009 · PMID 19767206
2 measurements at 2 targets · Measurements
Rimonabant
118
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile
Silvestri R, Ligresti A, La Regina G et al. · Bioorganic & medicinal chemistry 2009 · PMID 19595596
2 measurements at 2 targets · Measurements
Rimonabant
119
Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter
Ben-Daniel R, Deuther-Conrad W, Scheunemann M et al. · Bioorganic & medicinal chemistry 2008 · PMID 18487050
2 measurements at 1 target · Measurements
MDMA
120
Discovery of a novel class of selective human CB1 inverse agonists
Foloppe N, Allen NH, Bentley CH et al. · Bioorganic & medicinal chemistry letters 2008 · PMID 18083560
2 measurements at 2 targets · Measurements
Rimonabant
121
Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo
Pasquini S, Botta L, Semeraro T et al. · Journal of medicinal chemistry 2008 · PMID 18680276
2 measurements at 2 targets · Measurements
Rimonabant
122
Novel sterically hindered cannabinoid CB1 receptor ligands
Urbani P, Cascio MG, Ramunno A et al. · Bioorganic & medicinal chemistry 2008 · PMID 18579386
2 measurements at 2 targets · Measurements
Rimonabant
123
Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant
Menozzi G, Fossa P, Cichero E et al. · European journal of medicinal chemistry 2008 · PMID 18342403
2 measurements at 2 targets · Measurements
Rimonabant
124
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides
Silvestri R, Cascio MG, La Regina G et al. · Journal of medicinal chemistry 2008 · PMID 18293908
2 measurements at 2 targets · Measurements
Rimonabant
125
Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model
Srivastava BK, Joharapurkar A, Raval S et al. · Journal of medicinal chemistry 2007 · PMID 17979261
2 measurements at 2 targets · Measurements
Rimonabant
126
Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists
Lange JH, van Stuivenberg HH, Coolen HK et al. · Journal of medicinal chemistry 2005 · PMID 15771428
2 measurements at 2 targets · Measurements
Rimonabant
127
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo
Wang Y, Tang K, Inan S et al. · The Journal of pharmacology and experimental therapeutics 2005 · PMID 15383632
2 measurements at 1 target · Measurements
Salvinorin A
128
Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors
Yan F, Mosier PD, Westkaemper RB et al. · Biochemistry 2005 · PMID 15952771
2 measurements at 1 target · Measurements
Salvinorin A
129
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization
Millan MJ, Newman-Tancredi A, Lochon S et al. · Pharmacology, biochemistry, and behavior 2002 · PMID 11888550
2 measurements at 1 target · Measurements
Methysergide
130
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle
Bach T, Syversveen T, Kvingedal AM et al. · Naunyn-Schmiedeberg's archives of pharmacology 2001 · PMID 11218067
2 measurements at 2 targets · Measurements
5-Methoxytryptamine
131
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor
Wainscott DB, Sasso DA, Kursar JD et al. · Naunyn-Schmiedeberg's archives of pharmacology 1998 · PMID 9459568
2 measurements at 1 target · Measurements
Methysergide
132
Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase
Claeysen S, Faye P, Sebben M et al. · Neuroreport 1997 · PMID 9351641
2 measurements at 1 target · Measurements
5-Methoxytryptamine
133
Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline
Seeman P, Guan HC, Nobrega J et al. · Synapse (New York, N.Y.) 1997 · PMID 9021894
2 measurements at 1 target · Measurements
Bromocriptine
134
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor
Adham N, Gerald C, Schechter L et al. · European journal of pharmacology 1996 · PMID 8813606
2 measurements at 1 target · Measurements
5-Methoxytryptamine
135
Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor
Claeysen S, Sebben M, Journot L et al. · FEBS letters 1996 · PMID 8946946
2 measurements at 1 target · Measurements
5-Methoxytryptamine
136
Expression and pharmacological characterization of the human D3 dopamine receptor
Freedman SB, Patel S, Marwood R et al. · The Journal of pharmacology and experimental therapeutics 1994 · PMID 8301582
2 measurements at 2 targets · Measurements
Bromocriptine
137
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor
Kursar JD, Nelson DL, Wainscott DB et al. · Molecular pharmacology 1994 · PMID 8078486
2 measurements at 1 target · Measurements
DOI
138
[3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus
Bonhaus DW, Loury DN, Jakeman LB et al. · The Journal of pharmacology and experimental therapeutics 1993 · PMID 8246171
2 measurements at 1 target · Measurements
Phencyclidine (PCP)
139
Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms
Sundaram H, Newman-Tancredi A, Strange PG · Biochemical pharmacology 1993 · PMID 8461029
2 measurements at 1 target · Measurements
Lisuride
140
Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain
Grossman CJ, Kilpatrick GJ, Bunce KT · British journal of pharmacology 1993 · PMID 8358562
2 measurements at 1 target · Measurements
5-Methoxytryptamine
141
Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective
Seeman P, Van Tol HH · European journal of pharmacology 1993 · PMID 8097160
2 measurements at 2 targets · Measurements
Bromocriptine
142
Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain
Levant B, Grigoriadis DE, DeSouza EB · The Journal of pharmacology and experimental therapeutics 1992 · PMID 1356154
2 measurements at 1 target · Measurements
Bromocriptine
143
Pharmacological characterization of a novel muscarinic partial agonist, YM796, in transfected cells expressing the m1 or m2 muscarinic receptor gene
Wei HB, Roeske WR, Lai J et al. · Life sciences 1992 · PMID 1310135
2 measurements at 2 targets · Measurements
Arecoline
144
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara RK, Guan HC, O'Dowd BF et al. · Nature 1991 · PMID 1826762
2 measurements at 2 targets · Measurements
Bromocriptine
145
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
Sokoloff P, Giros B, Martres MP et al. · Nature 1990 · PMID 1975644
2 measurements at 2 targets · Measurements
Bromocriptine
146
Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum
Billard W, Ruperto V, Crosby G et al. · Life sciences 1984 · PMID 6387355
2 measurements at 2 targets · Measurements
Methysergide
147
Freezing and freeze-drying
Rey L · Proceedings of the Royal Society of London. Series B, Biological sciences 1975 · PMID 1775
2 measurements at 2 targets · Measurements
Rimonabant
148
Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy
Bricker BA, Peprah K, Kang HJ et al. · Pharmacology, biochemistry, and behavior 2019 · PMID 30768942
1 measurement at 1 target · Measurements
Methysergide
149
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties
Kang H, Park P, Bortolotto ZA et al. · Neuropharmacology 2017 · PMID 27520396
1 measurement at 1 target · Measurements
Ketamine
150
Molecular interactions between general anesthetics and the 5HT2B receptor
Matsunaga F, Gao L, Huang XP et al. · Journal of biomolecular structure & dynamics 2015 · PMID 24365264
1 measurement at 1 target · Measurements
Methysergide
151
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring
Bonifazi A, Del Bello F, Mammoli V et al. · Journal of medicinal chemistry 2015 · PMID 26430967
1 measurement at 1 target · Measurements
Phencyclidine (PCP)
152
Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor
Polepally PR, Huben K, Vardy E et al. · European journal of medicinal chemistry 2014 · PMID 25193297
1 measurement at 1 target · Measurements
Salvinorin A
153
Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands
Furlotti G, Alisi MA, Apicella C et al. · Journal of medicinal chemistry 2012 · PMID 23043420
1 measurement at 1 target · Measurements
Methysergide
154
1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists
Hou DR, Alam S, Kuan TC et al. · Bioorganic & medicinal chemistry letters 2009 · PMID 19095444
1 measurement at 1 target · Measurements
Rimonabant
155
Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles
Dow RL, Hadcock JR, Scott DO et al. · Bioorganic & medicinal chemistry letters 2009 · PMID 19683918
1 measurement at 1 target · Measurements
Rimonabant
156
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation
Ghirmai S, Azar MR, Cashman JR · Bioorganic & medicinal chemistry 2009 · PMID 19683449
1 measurement at 1 target · Measurements
Salvinorin A
157
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
Alig L, Alsenz J, Andjelkovic M et al. · Journal of medicinal chemistry 2008 · PMID 18335976
1 measurement at 1 target · Measurements
Rimonabant
158
Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B
Bikbulatov RV, Yan F, Roth BL et al. · Bioorganic & medicinal chemistry letters 2007 · PMID 17303418
1 measurement at 1 target · Measurements
Salvinorin A
159
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity
Smith RA, Fathi Z, Achebe F et al. · Bioorganic & medicinal chemistry letters 2007 · PMID 17383180
1 measurement at 1 target · Measurements
Rimonabant
160
Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes
Ghoneim OM, Legere JA, Golbraikh A et al. · Bioorganic & medicinal chemistry 2006 · PMID 16782354
1 measurement at 1 target · Measurements
Methysergide
161
Binding properties of dipropyltryptamine at the human 5-HT1a receptor
Thiagaraj HV, Russo EB, Burnett A et al. · Pharmacology 2005 · PMID 15886504
1 measurement at 1 target · Measurements
N,N-Dipropyltryptamine (DPT)
162
Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors
Brizzi A, Brizzi V, Cascio MG et al. · Journal of medicinal chemistry 2005 · PMID 16279794
1 measurement at 1 target · Measurements
HU-210
163
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist
Munro TA, Rizzacasa MA, Roth BL et al. · Journal of medicinal chemistry 2005 · PMID 15658846
1 measurement at 1 target · Measurements
Salvinorin A
164
Trace amines: identification of a family of mammalian G protein-coupled receptors
Borowsky B, Adham N, Jones KA et al. · Proceedings of the National Academy of Sciences of the United States of America 2001 · PMID 11459929
1 measurement at 1 target · Measurements
Tryptamine
165
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states
Millan MJ, Newman-Tancredi A, Audinot V et al. · Synapse (New York, N.Y.) 2000 · PMID 10611634
1 measurement at 1 target · Measurements
Tryptamine
166
Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections
Mutel V, Ellis GJ, Adam G et al. · Journal of neurochemistry 2000 · PMID 11080213
1 measurement at 1 target · Measurements
Ibotenic acid
167
Correlation of the apparent affinities and efficacies of gamma-aminobutyric acid(C) receptor agonists
Chang Y, Covey DF, Weiss DS · Molecular pharmacology 2000 · PMID 11093776
1 measurement at 1 target · Measurements
Muscimol
168
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
Seeman P, Tallerico T · Molecular psychiatry 1998 · PMID 9577836
1 measurement at 1 target · Measurements
Bromocriptine
169
Characterization of (2S,2'R,3'R)-2-(2',3'-[3H]-dicarboxycyclopropyl)glycine binding in rat brain
Mutel V, Adam G, Chaboz S et al. · Journal of neurochemistry 1998 · PMID 9832156
1 measurement at 1 target · Measurements
Ibotenic acid
170
Activity of Parthenolide at 5HT2A receptors
Weber JT, O'Connor MF, Hayataka K et al. · Journal of natural products 1997 · PMID 9214741
1 measurement at 1 target · Measurements
Methysergide
171
Pharmacology and functions of metabotropic glutamate receptors
Conn PJ, Pin JP · Annual review of pharmacology and toxicology 1997 · PMID 9131252
1 measurement at 1 target · Measurements
Ibotenic acid
172
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Schotte A, Janssen PF, Gommeren W et al. · Psychopharmacology 1996 · PMID 8935801
1 measurement at 1 target · Measurements
Methysergide
173
BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex
Borsini F, Giraldo E, Monferini E et al. · Naunyn-Schmiedeberg's archives of pharmacology 1995 · PMID 8584042
1 measurement at 1 target · Measurements
Methysergide
174
Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1
Joly C, Gomeza J, Brabet I et al. · The Journal of neuroscience : the official journal of the Society for Neuroscience 1995 · PMID 7751958
1 measurement at 1 target · Measurements
Ibotenic acid
175
Characterization of a 5-hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells
Unsworth CD, Molinoff PB · The Journal of pharmacology and experimental therapeutics 1994 · PMID 8169832
1 measurement at 1 target · Measurements
5-Methoxytryptamine
176
Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding
Schiavi GB, Brunet S, Rizzi CA et al. · Neuropharmacology 1994 · PMID 7984293
1 measurement at 1 target · Measurements
5-Methoxytryptamine
177
Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells
Pauwels PJ, Van Gompel P, Leysen JE · Biochemical pharmacology 1993 · PMID 8382063
1 measurement at 1 target · Measurements
DOM
178
Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity
Hamblin MW, Metcalf MA, McGuffin RW et al. · Biochemical and biophysical research communications 1992 · PMID 1315531
1 measurement at 1 target · Measurements
5-Methoxytryptamine
179
Pharmacologic comparison of selected agonists for the M1 muscarinic receptor in transfected murine fibroblast cells (B82)
Mei L, Lai J, Yamamura HI et al. · The Journal of pharmacology and experimental therapeutics 1991 · PMID 1704434
1 measurement at 1 target · Measurements
Arecoline
180
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor
Hamblin MW, Metcalf MA · Molecular pharmacology 1991 · PMID 1652050
1 measurement at 1 target · Measurements
5-Methoxytryptamine
181
Regulation of dopamine D2 receptors by sodium and pH
Neve KA · Molecular pharmacology 1991 · PMID 2017157
1 measurement at 1 target · Measurements
Bromocriptine
182
Characterization of D1 dopamine receptors in the bovine pineal gland with [3H]SCH 23390
Simonneaux V, Murrin LC, Ebadi M · The Journal of pharmacology and experimental therapeutics 1990 · PMID 2139469
1 measurement at 1 target · Measurements
Methysergide
183
Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine
Kovachich GB, Aronson CE, Brunswick DJ et al. · Brain research 1988 · PMID 2970277
1 measurement at 1 target · Measurements
Methysergide
184
Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine
Tran VT, Chang RS, Snyder SH · Proceedings of the National Academy of Sciences of the United States of America 1978 · PMID 282646
1 measurement at 1 target · Measurements
LSD
185
Beta adrenergic receptor binding in membrane preparations from mammalian brain
Bylund DB, Snyder SH · Molecular pharmacology 1976 · PMID 8699
1 measurement at 1 target · Measurements
DOET
186
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
Ley L, Holze F, Arikci D et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2023 · PMID 37231080
Acute effects, Reported milestones
LSD, Mescaline, Psilocin, Psilocybin
187
Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants
Arikci D, Borgulya J, Straumann I et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2026 · PMID 42049943
Acute effects
2C-B, MDMA, Psilocybin
188
Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants
Straumann I, Vizeli P, Avedisian I et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2026 · PMID 40999236
Acute effects
MDA, MDMA
189
Beyond THC: The New Generation of Cannabinoid Designer Drugs
Fattore L, Fratta W · Frontiers in behavioral neuroscience 2011 · PMID 22007163
Pharmacology, Toxicology
JWH-018, JWH-073
190
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior
González-Maeso J, Weisstaub NV, Zhou M et al. · Neuron 2007 · PMID 17270739
Pharmacology
LSD, Mescaline
191
Landmark
Psychedelics align brain activity with context
Stoliker D, Novelli L, Khajehnejad M et al. · Nature 2026 · PMID 42618786
Reported milestones
Psilocin
Why it matters · written by this site
A brain-imaging study rather than a pharmacological one p. Sixty-two adults with no previous psychedelic experience were imaged with fMRI and 64-channel EEG in four contexts — eyes-closed rest, guided meditation and music, and an eyes-open movie — at a baseline session and again after a single 19 mg oral dose of psilocybin p. What it reports is a redistribution rather than a loss of order: global functional connectivity fell in sensory cortex and rose in associative cortex during the eyes-closed conditions, the gap between eyes-closed and eyes-open connectivity narrowed in every network, and the later EEG block found the same convergence in alpha power p. Low-dimensional embeddings of each participant's dynamics separated the four contexts under psilocybin and not at baseline, and that separation was graded by the participants' own ratings of self-dissolving and boundary-dissolving experience p. Three of the six reported milestones on this archive's psilocin simulation are taken from it — at the two times it states for its scans, and at its day-after follow-up — and it supplies no measurement row anywhere on this site a.
Verified Full text read from the published PDF: article, Methods, the figure and Extended Data captions, and the Reporting Summary. The Supplementary Information and the Extended Data figures themselves were not read, so nothing that appears only there is claimed above. The design is open-label and unblinded at every stage including analysis, with each participant's baseline session about a week earlier as the only comparison — there is no placebo arm, and that is stated here because it is the weakest design of any work this archive draws a time from. Analysed sample sizes vary by condition after quality control (fMRI 56-60 per condition, EEG 58, and 54 for the embedding analyses), so the sixty-two above is the number imaged in both sessions and not the n behind any single result. What the milestones do and do not take from it is recorded in tools/effect_milestones.json.
Not supported Anything connecting these findings to the rest of this site. The paper reports no binding, no occupancy and no plasma concentration, so none of it can be checked against the affinity tables the simulation computes occupancy from, and the milestones drawn from it sit beside the modelled curve rather than being derived from it. Its P values for the network comparisons are computed across cortical vertices rather than across participants and are not quoted anywhere here. Its brain maps are not shown at all: the archive's regional figures are transcript levels from the Human Protein Atlas, a different quantity in a different parcellation, and drawing a connectivity change on them would assert a correspondence nobody has published.
192
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Vogt SB, Ley L, Erne L et al. · Translational psychiatry 2023 · PMID 37221177
Reported milestones
Dimethyltryptamine (DMT)
193
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
Holze F, Becker AM, Kolaczynska KE et al. · Clinical pharmacology and therapeutics 2023 · PMID 36507738
Acute effects
Psilocin
194
Pharmacokinetics of N,N-dimethyltryptamine in Humans
Good M, Joel Z, Benway T et al. · European journal of drug metabolism and pharmacokinetics 2023 · PMID 37086340
Acute effects
Dimethyltryptamine (DMT)
195
The clinical toxicology of ketamine
Schep LJ, Slaughter RJ, Watts M et al. · Clinical toxicology (Philadelphia, Pa.) 2023 · PMID 37267048
Acute effects
Ketamine
196
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects
Becker AM, Holze F, Grandinetti T et al. · Clinical pharmacology and therapeutics 2022 · PMID 34743319
Acute effects
Psilocybin
197
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Holze F, Vizeli P, Ley L et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2021 · PMID 33059356
Acute effects
LSD
198
Determining the magnitude and duration of acute Δ(9)-tetrahydrocannabinol (Δ(9)-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review
McCartney D, Arkell TR, Irwin C et al. · Neuroscience and biobehavioral reviews 2021 · PMID 33497784
Acute effects
Tetrahydrocannabinol (THC)
199
Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine
Maxwell EA, King TI, Kamble SH et al. · European journal of drug metabolism and pharmacokinetics 2021 · PMID 33847897
Acute effects
7-Hydroxymitragynine
200
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
Arkell TR, Lintzeris N, Kevin RC et al. · Psychopharmacology 2019 · PMID 31044290
Reported milestones
Tetrahydrocannabinol (THC)
201
Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations
Müller F, Lenz C, Dolder P et al. · Acta psychiatrica Scandinavica 2017 · PMID 28940312
Toxicology
LSD
202
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Dolder PC, Schmid Y, Steuer AE et al. · Clinical pharmacokinetics 2017 · PMID 28197931
Acute effects
LSD
203
Safety pharmacology of acute MDMA administration in healthy subjects
Vizeli P, Liechti ME · Journal of psychopharmacology (Oxford, England) 2017 · PMID 28443695
Reported milestones
MDMA
204
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships
Hartman RL, Brown TL, Milavetz G et al. · Drug testing and analysis 2016 · PMID 26257143
Acute effects
Tetrahydrocannabinol (THC)
205
Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex
McClatchy DB, Savas JN, Martínez-Bartolomé S et al. · Molecular psychiatry 2016 · PMID 25869802
Pharmacology
Phencyclidine (PCP)
206
Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress
Baker SC, Shabir S, Georgopoulos NT et al. · The American journal of pathology 2016 · PMID 27001627
Pharmacology
Ketamine
207
Role of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine and valerenic acid in the rat formalin test
Vidal-Cantú GC, Jiménez-Hernández M, Rocha-González HI et al. · European journal of pharmacology 2016 · PMID 27068146
Pharmacology
Ergotamine
208
Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans
Johnson MW, MacLean KA, Caspers MJ et al. · Journal of psychopharmacology (Oxford, England) 2016 · PMID 26880225
Toxicology
Salvinorin A
209
Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability
Glue P, Lockhart M, Lam F et al. · Journal of clinical pharmacology 2015 · PMID 25279818
Acute effects
Noribogaine
210
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart
Farré M, Tomillero A, Pérez-Mañá C et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2015 · PMID 26073279
Toxicology
MDMA
211
Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET
Placzek MS, Van de Bittner GC, Wey HY et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2015 · PMID 26058662
Acute effects, Pharmacology
Salvinorin A
212
Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers
Glue P, Winter H, Garbe K et al. · Journal of clinical pharmacology 2015 · PMID 25651476
Acute effects
Ibogaine
213
Ketamine-Induced Hallucinations
Powers AR 3rd, Gancsos MG, Finn ES et al. · Psychopathology 2015 · PMID 26361209
Toxicology
Ketamine
214
Mania after misuse of dextromethorphan: a case report and brief review of "robotripping"
Stanciu CN, Penders TM · Journal of addiction medicine 2015 · PMID 25622122
Toxicology
Dextromethorphan
215
N-methyl-D-aspartate receptor channel blocker-like discriminative stimulus effects of nitrous oxide gas
Richardson KJ, Shelton KL · The Journal of pharmacology and experimental therapeutics 2015 · PMID 25368340
Pharmacology
Nitrous oxide
216
Pharmacokinetics of mitragynine in man
Trakulsrichai S, Sathirakul K, Auparakkitanon S et al. · Drug design, development and therapy 2015 · PMID 25995615
Acute effects
Mitragynine
217
Tetrahydrocannabinol induces brain mitochondrial respiratory chain dysfunction and increases oxidative stress: a potential mechanism involved in cannabis-related stroke
Wolff V, Schlagowski AI, Rouyer O et al. · BioMed research international 2015 · PMID 25654095
Pharmacology
Tetrahydrocannabinol (THC)
218
The Effects of Dextromethorphan on Driving Performance and the Standardized Field Sobriety Test
Perry PJ, Fredriksen K, Chew S et al. · Journal of forensic sciences 2015 · PMID 26294136
Toxicology
Dextromethorphan
219
The subjective experience of acute, experimentally-induced Salvia divinorum inebriation
Addy PH, Garcia-Romeu A, Metzger M et al. · Journal of psychopharmacology (Oxford, England) 2015 · PMID 25691501
Toxicology
Salvinorin A
220
Δ9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8
Sido JM, Yang X, Nagarkatti PS et al. · Journal of leukocyte biology 2015 · PMID 25713087
Pharmacology
Tetrahydrocannabinol (THC)
221
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors
Rubio-Araiz A, Perez-Hernandez M, Urrutia A et al. · The international journal of neuropsychopharmacology 2014 · PMID 24626059
Pharmacology
MDMA
222
Acute phencyclidine treatment induces extensive and distinct protein phosphorylation in rat frontal cortex
Palmowski P, Rogowska-Wrzesinska A, Williamson J et al. · Journal of proteome research 2014 · PMID 24564430
Pharmacology
Phencyclidine (PCP)
223
Evaluation of the mutagenicity and genotoxic potential of carvacrol and thymol using the Ames Salmonella test and alkaline, Endo III- and FPG-modified comet assays with the human cell line Caco-2
LLana-Ruiz-Cabello M, Maisanaba S, Puerto M et al. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2014 · PMID 25038394
Toxicology
Thymol
224
Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier
Gu D, Huang J, Yin Y et al. · Molecular biology reports 2014 · PMID 25091940
Pharmacology
Ketamine
225
MDMA decreases the effects of simulated social rejection
Frye CG, Wardle MC, Norman GJ et al. · Pharmacology, biochemistry, and behavior 2014 · PMID 24316346
Toxicology
MDMA
226
Potentiation of macrophage activity by thymol through augmenting phagocytosis
Chauhan AK, Jakhar R, Paul S et al. · International immunopharmacology 2014 · PMID 24316253
Pharmacology
Thymol
227
Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control
Rasmussen KG · Acta neuropsychiatrica 2014 · PMID 25142291
Toxicology
Ketamine
228
Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex
Nishitani N, Nagayasu K, Asaoka N et al. · The international journal of neuropsychopharmacology 2014 · PMID 24852262
Pharmacology
Ketamine
229
Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism
Kivell B, Uzelac Z, Sundaramurthy S et al. · Neuropharmacology 2014 · PMID 25107591
Pharmacology
Salvinorin A
230
The mixture of "ecstasy" and its metabolites impairs mitochondrial fusion/fission equilibrium and trafficking in hippocampal neurons, at in vivo relevant concentrations
Barbosa DJ, Serrat R, Mirra S et al. · Toxicological sciences : an official journal of the Society of Toxicology 2014 · PMID 24595818
Pharmacology
MDMA
231
The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain
Issa MA, Narang S, Jamison RN et al. · The Clinical journal of pain 2014 · PMID 24281276
Toxicology
Tetrahydrocannabinol (THC)
232
Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans
Carter LP, Reissig CJ, Johnson MW et al. · Drug and alcohol dependence 2013 · PMID 22989498
Toxicology
Dextromethorphan
233
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
MacLean KA, Johnson MW, Reissig CJ et al. · Psychopharmacology 2013 · PMID 23135605
Toxicology
Salvinorin A
234
Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation
Antonio T, Childers SR, Rothman RB et al. · PloS one 2013 · PMID 24204784
Pharmacology
Ibogaine
235
Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material
Mazoyer C, Carlier J, Boucher A et al. · Journal of forensic sciences 2013 · PMID 23919354
Toxicology
Ibogaine
236
Ibogaine related sudden death: a case report
Papadodima SA, Dona A, Evaggelakos CI et al. · Journal of forensic and legal medicine 2013 · PMID 24112325
Toxicology
Ibogaine
237
Involvement of the N-methyl-D-aspartate receptor GluN2D subunit in phencyclidine-induced motor impairment, gene expression, and increased Fos immunoreactivity
Yamamoto H, Kamegaya E, Sawada W et al. · Molecular brain 2013 · PMID 24330819
Pharmacology
Phencyclidine (PCP)
238
NMDA receptor antagonist ketamine impairs feature integration in visual perception
Meuwese JD, van Loon AM, Scholte HS et al. · PloS one 2013 · PMID 24223927
Toxicology
Ketamine
239
Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system
Hoffman AF, Lupica CR · Cold Spring Harbor perspectives in medicine 2013 · PMID 23209160
Pharmacology
Tetrahydrocannabinol (THC)
240
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors
Paquette MA, Martinez AA, Macheda T et al. · The European journal of neuroscience 2012 · PMID 22861201
Pharmacology
Dextromethorphan
241
Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)
Pardo-Lozano R, Farré M, Yubero-Lahoz S et al. · PloS one 2012 · PMID 23112822
Toxicology
MDMA
242
Fatalities temporally associated with the ingestion of ibogaine
Alper KR, Stajić M, Gill JR · Journal of forensic sciences 2012 · PMID 22268458
Toxicology
Ibogaine
243
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
Reissig CJ, Carter LP, Johnson MW et al. · Psychopharmacology 2012 · PMID 22526529
Toxicology
Dextromethorphan
244
Life-threatening complications of ibogaine: three case reports
Paling FP, Andrews LM, Valk GD et al. · The Netherlands journal of medicine 2012 · PMID 23123541
Toxicology
Ibogaine
245
Performance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophrenia
Evans S, Almahdi B, Sultan P et al. · Journal of psychopharmacology (Oxford, England) 2012 · PMID 22389244
Toxicology
Ketamine
246
Cytotoxicity and accumulation of ergot alkaloids in human primary cells
Mulac D, Humpf HU · Toxicology 2011 · PMID 21295106
Toxicology
Ergocristine
247
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum
Johnson MW, MacLean KA, Reissig CJ et al. · Drug and alcohol dependence 2011 · PMID 21131142
Toxicology
Salvinorin A
248
MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study
Kuypers KP, Wingen M, Heinecke A et al. · Journal of psychopharmacology (Oxford, England) 2011 · PMID 21616977
Pharmacology
MDMA
249
Methylone and monoamine transporters: correlation with toxicity
Sogawa C, Sogawa N, Ohyama K et al. · Current neuropharmacology 2011 · PMID 21886563
Pharmacology
Methylone
250
[Krypton--new, deadly Internet drug. Since October 2009 have nine young persons died in Sweden]
Bäckstrom BG, Classon G, Löwenhielm P et al. · Lakartidningen 2010 · PMID 21294331
Toxicology
Mitragynine
251
Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents
Walentiny DM, Vann RE, Warner JA et al. · Psychopharmacology 2010 · PMID 20354680
Pharmacology
Salvinorin A
252
Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics
de Moraes NV, Moretti RA, Furr EB 3rd et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009 · PMID 19589735
Pharmacology
Mitragynine
253
Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans
Mueller M, Kolbrich EA, Peters FT et al. · Therapeutic drug monitoring 2009 · PMID 19417716
Pharmacology
MDMA
254
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat
Baumann MH, Zolkowska D, Kim I et al. · Drug metabolism and disposition: the biological fate of chemicals 2009 · PMID 19679675
Pharmacology
MDMA
255
When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor
Su TP, Hayashi T, Vaupel DB · Science signaling 2009 · PMID 19278957
Pharmacology
Dimethyltryptamine (DMT)
256
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
Thomsen WJ, Grottick AJ, Menzaghi F et al. · The Journal of pharmacology and experimental therapeutics 2008 · PMID 18252809
Pharmacology
Lorcaserin
257
Opioid receptors and legal highs: Salvia divinorum and Kratom
Babu KM, McCurdy CR, Boyer EW · Clinical toxicology (Philadelphia, Pa.) 2008 · PMID 18259963
Pharmacology
Mitragynine
258
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)
Boyer EW, Babu KM, Adkins JE et al. · Addiction (Abingdon, England) 2008 · PMID 18482427
Toxicology
Mitragynine
259
Syrian rue tea: a recipe for disaster
Yuruktumen A, Karaduman S, Bengi F et al. · Clinical toxicology (Philadelphia, Pa.) 2008 · PMID 18803088
Toxicology
Harmaline
260
Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial
Myles PS, Leslie K, Chan MT et al. · Anesthesiology 2007 · PMID 17667565
Toxicology
Nitrous oxide
261
Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor
Hewton R, Salem A, Irvine RJ · Clinical and experimental pharmacology & physiology 2007 · PMID 17714093
Pharmacology
p-Methoxyamphetamine
262
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai F, Nonaka R, Satoh Hisashi Kamimura K · European journal of pharmacology 2007 · PMID 17223101
Pharmacology
Methylone
263
Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction
Maas U, Strubelt S · Medical hypotheses 2006 · PMID 16698188
Toxicology
Ibogaine
264
In vitro biological efficiency of tenocyclidine-TCP and its adamantane derivative TAMORF
Radić B, Vrdoljak AL, Petek MJ et al. · Toxicology in vitro : an international journal published in association with BIBRA 2006 · PMID 16942853
Toxicology
Tenocyclidine
265
Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006 · PMID 16123739
Toxicology
Dimethyltryptamine (DMT)
266
Within-subject comparison of the subjective and psychomotor effects of a gaseous anesthetic and two volatile anesthetics in healthy volunteers
Beckman NJ, Zacny JP, Walker DJ · Drug and alcohol dependence 2006 · PMID 16024183
Toxicology
Nitrous oxide
267
Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption
He DY, McGough NN, Ravindranathan A et al. · The Journal of neuroscience : the official journal of the Society for Neuroscience 2005 · PMID 15659598
Pharmacology
Ibogaine
268
Protective effect of dextromethorphan against endotoxic shock in mice
Li G, Liu Y, Tzeng NS et al. · Biochemical pharmacology 2005 · PMID 15627475
Pharmacology
Dextromethorphan
269
[Chronic ergotism: spinal lesion and neuropathy]
Sallansonnet-Froment M, Guegan-Massardier E, Blohorn-Sense A et al. · Revue neurologique 2004 · PMID 15454875
Toxicology
Methysergide
270
5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs
Valdivia LF, Centurión D, Arulmani U et al. · Naunyn-Schmiedeberg's archives of pharmacology 2004 · PMID 15224175
Pharmacology
Ergotamine
271
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study
Hasler F, Grimberg U, Benz MA et al. · Psychopharmacology 2004 · PMID 14615876
Reported milestones
Psilocin
272
Antinociceptive effects of methysergide in various pain models
Chung KM, Choi SS, Han KJ et al. · Pharmacology 2003 · PMID 12928583
Pharmacology
Methysergide
273
Hepatoprotective effect of myristicin from nutmeg (Myristica fragrans) on lipopolysaccharide/d-galactosamine-induced liver injury
Morita T, Jinno K, Kawagishi H et al. · Journal of agricultural and food chemistry 2003 · PMID 12617584
Pharmacology
Myristicin
274
Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects
Refstad S · Acta anaesthesiologica Scandinavica 2003 · PMID 14616331
Toxicology
p-Methoxyamphetamine
275
Three fatal cases of PMA and PMMA poisoning in Denmark
Johansen SS, Hansen AC, Müller IB et al. · Journal of analytical toxicology 2003 · PMID 12820749
Toxicology
p-Methoxyamphetamine
276
Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors
Gresch PJ, Strickland LV, Sanders-Bush E · Neuroscience 2002 · PMID 12220572
Pharmacology
LSD
277
Re-evaluation of phencyclidine low-affinity or "non-NMDA" binding sites
Hirbec H, Mausset AL, Kamenka JM et al. · Journal of neuroscience research 2002 · PMID 12111860
Pharmacology
Tenocyclidine
278
Abuse of telazol: an animal tranquilizer
Quail MT, Weimersheimer P, Woolf AD et al. · Journal of toxicology. Clinical toxicology 2001 · PMID 11527235
Toxicology
Tiletamine
279
Comparative study on the vasorelaxant effects of three harmala alkaloids in vitro
Shi CC, Liao JF, Chen CF · Japanese journal of pharmacology 2001 · PMID 11325023
Pharmacology
Harmaline
280
Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains
Ouagazzal A, Grottick AJ, Moreau J et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001 · PMID 11557170
Pharmacology
LSD
281
Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA)
Kraner JC, McCoy DJ, Evans MA et al. · Journal of analytical toxicology 2001 · PMID 11599617
Toxicology
p-Methoxyamphetamine
282
Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase
Bodur E, Cokuğraş AN, Tezcan EF · Archives of biochemistry and biophysics 2001 · PMID 11360997
Pharmacology
Benactyzine
283
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes
Kashima K, Tachibana H, Nakamura K et al. · Journal of cardiology 2001 · PMID 11433805
Toxicology
Ergonovine
284
A fatality due to injection of tiletamine and zolazepam
Chung H, Choi H, Kim E et al. · Journal of analytical toxicology 2000 · PMID 10872580
Toxicology
Tiletamine
285
Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat
Daws LC, Irvine RJ, Callaghan PD et al. · Progress in neuro-psychopharmacology & biological psychiatry 2000 · PMID 11041537
Pharmacology
p-Methoxyamphetamine
286
Excitation of nigral dopamine neurons by the GABA(A) receptor agonist muscimol is mediated via release of glutamate
Erhardt S, Engberg G · Life sciences 2000 · PMID 11043612
Pharmacology
Muscimol
287
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
Kelly PA · Journal of neurology, neurosurgery, and psychiatry 2000 · PMID 10811690
Toxicology
MDMA
288
Long-lasting ibogaine protection against NMDA-induced convulsions in mice
Leal MB, de Souza DO, Elisabetsky E · Neurochemical research 2000 · PMID 11055745
Pharmacology
Ibogaine
289
Pharmacokinetic characterization of the indole alkaloid ibogaine in rats
Hough LB, Bagal AA, Glick SD · Methods and findings in experimental and clinical pharmacology 2000 · PMID 10849889
Pharmacology
Ibogaine
290
A fatality related to the veterinary anesthetic telazol
Cording CJ, DeLuca R, Camporese T et al. · Journal of analytical toxicology 1999 · PMID 10517567
Toxicology
Tiletamine
291
Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans
Mas M, Farré M, de la Torre R et al. · The Journal of pharmacology and experimental therapeutics 1999 · PMID 10381769
Pharmacology
MDMA
292
Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine
Alburges ME, Hanson GR · Brain research 1999 · PMID 9914442
Pharmacology
Ibogaine
293
Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines
Cozzi NV, Sievert MK, Shulgin AT et al. · European journal of pharmacology 1999 · PMID 10528135
Pharmacology
Methylone
294
Long-term changes in brain following continuous phencyclidine administration: an autoradiographic study using flunitrazepam, ketanserin, mazindol, quinuclidinyl benzilate, piperidyl-3,4-3H(N)-TCP, and AMPA receptor ligands
Ellison G, Keys A, Noguchi K · Pharmacology & toxicology 1999 · PMID 9974184
Pharmacology
Tenocyclidine
295
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex
Arvanov VL, Liang X, Russo A et al. · The European journal of neuroscience 1999 · PMID 10510170
Pharmacology
LSD
296
Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration
Ebert U, Siepmann M, Oertel R et al. · Journal of clinical pharmacology 1998 · PMID 9725548
Acute effects
Scopolamine
297
Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features
Bucci JA, Manoharan A · Mayo Clinic proceedings 1997 · PMID 9413296
Toxicology
Methysergide
298
Murine Cyp1a-1 induction in mouse hepatoma Hepa-1C1C7 cells by myristicin
Jeong HG, Lee SS, Kim HK et al. · Biochemical and biophysical research communications 1997 · PMID 9168900
Pharmacology
Myristicin
299
Toxicological evaluation of myristicin
Hallström H, Thuvander A · Natural toxins 1997 · PMID 9496377
Toxicology
Myristicin
300
Fos-like immunoreactivity in the mamillary body and thalamus following injections of muscimol into the ventral tegmental nucleus of Gudden in the rat
Shim I, Wirtshafter D · Brain research 1996 · PMID 8814891
Pharmacology
Muscimol
301
Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects
Strassman RJ, Qualls CR · Archives of general psychiatry 1994 · PMID 8297216
Toxicology
Dimethyltryptamine (DMT)
302
Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale
Strassman RJ, Qualls CR, Uhlenhuth EH et al. · Archives of general psychiatry 1994 · PMID 8297217
Acute effects, Toxicology
Dimethyltryptamine (DMT)
303
Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors
Nash JF, Roth BL, Brodkin JD et al. · Neuroscience letters 1994 · PMID 7824160
Pharmacology
MDA
304
Pharmacokinetics and bioavailability of oral ergometrine in male volunteers
de Groot AN, Vree TB, Hekster YA et al. · Biopharmaceutics & drug disposition 1994 · PMID 8161717
Pharmacology
Ergonovine
305
Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission
Ghansah E, Kopsombut P, Malleque MA et al. · Neuropharmacology 1993 · PMID 8383816
Pharmacology
Mescaline
306
Multiple structural determinants of voltage-dependent magnesium block in recombinant NMDA receptors
Kawajiri S, Dingledine R · Neuropharmacology 1993 · PMID 8107974
Pharmacology
Tenocyclidine
307
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research
Hermle L, Fünfgeld M, Oepen G et al. · Biological psychiatry 1992 · PMID 1467389
Toxicology
Mescaline
308
3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine
McKenna DJ, Guan XM, Shulgin AT · Pharmacology, biochemistry, and behavior 1991 · PMID 1829838
Pharmacology
MDA
309
Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites
Rao TS, Contreras PC, Cler JA et al. · Journal of neurochemistry 1991 · PMID 1847186
Pharmacology
Tiletamine
310
Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors
Deliganis AV, Pierce PA, Peroutka SJ · Biochemical pharmacology 1991 · PMID 1828347
Pharmacology
Dimethyltryptamine (DMT)
311
Pharmacokinetics and distribution of ketamine after extradural administration to dogs
Pedraz JL, Calvo MB, Gascon AR et al. · British journal of anaesthesia 1991 · PMID 1911019
Pharmacology
Ketamine
312
[The mechanism of ergonovine-induced airway smooth muscle contraction]
Sakamoto Y · Nihon Kyobu Shikkan Gakkai zasshi 1989 · PMID 2796062
Pharmacology
Ergonovine
313
Effects of intracoronary injection of ergonovine on angiographic normal coronary arteries: study of 108 consecutive patients
Fournier JA, Cortacero JA, Turá A et al. · Clinical cardiology 1989 · PMID 2805461
Toxicology
Ergonovine
314
'Designer drugs'. A problem in clinical toxicology
Buchanan JF, Brown CR · Medical toxicology and adverse drug experience 1988 · PMID 3285124
Toxicology
MDA
315
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
Titeler M, Lyon RA, Glennon RA · Psychopharmacology 1988 · PMID 3127847
Pharmacology
DOM
316
The P-300 event-related potential in experimental nitrous oxide exposure
Estrin WJ, Moore P, Letz R et al. · Clinical pharmacology and therapeutics 1988 · PMID 3335122
Toxicology
Nitrous oxide
317
Agonist/antagonist activity of ergocristine at alpha-adrenoceptors in the rat
Roquebert J, Demichel P · Fundamental & clinical pharmacology 1987 · PMID 2822556
Pharmacology
Ergocristine
318
The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor
Amitai G, Herz JM, Bruckstein R et al. · Molecular pharmacology 1987 · PMID 3683366
Pharmacology
Benactyzine
319
Tiletamine is a potent inhibitor of N-methyl-aspartate-induced depolarizations in rat hippocampus and striatum
ffRench-Mullen JM, Lehmann J, Bohacek R et al. · The Journal of pharmacology and experimental therapeutics 1987 · PMID 3320347
Pharmacology
Tiletamine
320
Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system
Garattini S, Mennini T, Bendotti C et al. · Appetite 1986 · PMID 2427023
Pharmacology
Fenfluramine
321
Pharmacokinetics of methysergide and its metabolite methylergometrine in man
Bredberg U, Eyjolfsdottir GS, Paalzow L et al. · European journal of clinical pharmacology 1986 · PMID 3709634
Pharmacology
Methysergide
322
Possible involvement of serotonin receptors in the facilitatory effect of a hallucinogenic phenethylamine on single facial motoneurons
Penington NJ, Reiffenstein RJ · Canadian journal of physiology and pharmacology 1986 · PMID 3801984
Pharmacology
DOM
323
A mescaline associated fatality
Reynolds PC, Jindrich EJ · Journal of analytical toxicology 1985 · PMID 4033076
Toxicology
Mescaline
324
Clinical pharmacokinetics of ergotamine in migraine and cluster headache
Perrin VL · Clinical pharmacokinetics 1985 · PMID 3899452
Acute effects, Pharmacology
Ergotamine
325
Computerized assessment of human neurotoxicity: sensitivity to nitrous oxide exposure
Greenberg BD, Moore PA, Letz R et al. · Clinical pharmacology and therapeutics 1985 · PMID 4064468
Toxicology
Nitrous oxide
326
Intramuscular ergotamine: plasma levels and dynamic activity
Tfelt-Hansen P, Paalzow L · Clinical pharmacology and therapeutics 1985 · PMID 3917386
Toxicology
Ergotamine
327
Muscimol and some aza analogues: molecular orbital calculations relating to their potency as GABA mimetics
Armstrong DR, Breckenridge RJ, Suckling CJ · Journal of theoretical biology 1982 · PMID 6290798
Pharmacology
Muscimol
328
Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology
Simpson DL, Rumack BH · Archives of internal medicine 1981 · PMID 7283563
Toxicology
MDA
329
Effect of two antiserotoninergic drugs, methysergide and metergoline, on gastric acid secretion and gastrin release in healthy man
Caldara R, Ferrari C, Barbieri C et al. · European journal of clinical pharmacology 1980 · PMID 7371695
Toxicology
Methysergide
330
Effect of ergocristine on prolactin secretion in the male rat with pituitaries grafted beneath the kidney capsule
Shin SH · Canadian journal of physiology and pharmacology 1979 · PMID 42476
Pharmacology
Ergocristine
331
Fatal intoxication from 3,4-methylenedioxyamphetamine
Poklis A, Mackell MA, Drake WK · Journal of forensic sciences 1979 · PMID 512617
Toxicology
MDA
332
[Effects of N,N-dimethyltryptamine (DMT) on tests of psychoticism (author's transl)]
Bickel P, Dittrich A, Schöpf J · Pharmakopsychiatrie, Neuro-Psychopharmakologie 1977 · PMID 329291
Toxicology
Dimethyltryptamine (DMT)
333
The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent
Christian ST, Harrison R, Quayle E et al. · Biochemical medicine 1977 · PMID 20877
Pharmacology
Dimethyltryptamine (DMT)
334
Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP)
Cheng HC, Long JP, Barfknecht CF et al. · The Journal of pharmacology and experimental therapeutics 1973 · PMID 4719787
Pharmacology
DOM
335
Alterations in the nocturnal sleep cycle resulting from LSD
Muzio JN, Roffwarg HP, Kaufman E · Electroencephalography and clinical neurophysiology 1966 · PMID 4162426
Toxicology
LSD
336
PERSISTENCE OF LYSERGIC ACID DIETHYLAMIDE IN THE PLASMA OF HUMAN SUBJECTS
AGHAJANIAN GK, BING OH · Clinical pharmacology and therapeutics 1964 · PMID 14209776
Pharmacology
LSD
337
Quantitative studies in humans on the antagonism of lysergic acid diethylamide by chlorpromazine and phenoxybenzamine
MURPHREE HB · Clinical pharmacology and therapeutics 1962 · PMID 14477403
Toxicology
LSD

The notes

Who wrote what on this page

The distinction the rest of the site is built on, applied to its own bibliography.

Everything above a landmark note is a record, not a description. The title, journal, year and authors are whatever PubMed returned for the identifier. The counts beneath are this build’s own rows, computed when the page is rendered. Neither is written by hand, and neither says anything about a paper’s quality.

The 5 landmark notes are the exception, and they are the only prose on this site that describes a paper. They carry the same fence as the history notes on the compound dossiers: every factual claim carries a marker — p for the paper as it was read, a for this archive’s own rows — and each note records exactly what was read. For most of them that is the abstract and not the full text, which is stated rather than glossed over, because a note may not claim more than its reading supports.

A note is never written from general knowledge, and there is no note where the reading does not support one. One paper was considered and deliberately left without one:

Molecular biology of 5-HT receptors (Boess & Martin, Neuropharmacology 1994)

It contributes more measurement rows to this archive than any other paper, which is precisely why it is tempting to write a note about it from general knowledge. PubMed returns no abstract for it and nobody here has read the review. A note would therefore be a description of a paper this project has not opened.

Would need The review read, or at minimum an abstract to quote from.

Provenance

How this list is built

Four places in this archive cite a PubMed identifier: assay rows carrying a reference_pmid, the pharmacology passages quoted from PubChem, the toxicology passages, and the curated acute-effects table. All four are gathered here. tools/fetch_literature.py resolves each identifier against PubMed once and stores the bibliographic record — last resolved 2026-09-27.

Quarantined compounds are excluded inside the query rather than after it, so a record the site does not show cannot credit a paper with measurements. That is the same rule every other count on this site follows, and the integrity report says which records it applies to.